HAVN Life Sciences Aktie

CEO, Tim Moore will share recent partnership and distribution news and a roadmap for the Company's plans for the next quarterVancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Havn Life Sciences Inc. (CSE: HAVN) (OTC Pink: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and cognitive function, is announcing that CEO, Tim Moore will be presenting at the LD Micro Invitational XII, taking place June 7-9, 2022 at the Four Seasons Westlake Village in...» Mehr auf newsfilecorp.com

VANCOUVER, BC / ACCESSWIRE / April 30, 2022 / HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE:5NP) , a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, today announced that it will be presenting at the Planet MicroCap Showcase 2022 at the Bally's Hotel & Casino in Las Vegas, NV on Wednesday, May 4, 2022 at 9:00 a.m. PST. Tim Moore, CEO of HAVN Life Sciences Inc.,will be hosting the presentation and answering questions from investors.» Mehr auf accesswire.com

The partnership is a integral step in the The Company's path to market in the U.S., achieving one of its most important milestones to-date VANCOUVER, BC / ACCESSWIRE / September 23, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is thrilled to announce a partnership with California-based Mycrodose Therapeutics, one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds including psilocybin, MDMA, DMT, & LSD by the United States Drug Enforcement Agency (DEA). HAVN Life will work with its partners to export their naturally derived psilocybin to Mycrodose Therapeutics, where it will be used in the development of advanced drug delivery (ADD) systems to treat mental health and cognitive degenerative diseases, as well as be distributed to appropriately licenced customers in the U.S. "We are excited to have forged this partnership with Mycrodose Therapeutics, building an important link in our supply chain to service our Supply Agreement partners in the US," says HAVN Life CEO Tim Moore.» Mehr auf accesswire.com